Oncology Journals Help in the Fight Against Cancer and Improve the Quality of Life
SINGAPORE, and LONDON (PRWEB) November 06, 2018 -- Novel strategies of cancer treatment have seen a huge burst in recent years, offering significant clinical benefits to patients. The number of approved cancer treatments continues to rise, with 63 cancer drugs being launched within the last five years. All of the fourteen New Active Substance cancer therapies launched in 2017 were targeted therapies, 11 of which were granted the designation of Breakthrough Therapy by the FDA. However, the oncology market is still subject to a significant number of hurdles, with regulatory, clinical, and market access hurdles figuring prominently among them.
Nonetheless, oncology is the key driver of growth for the global pharmaceutical industry. It is projected to account for nearly 30% of the pharmaceutical product pipeline and 25% of the pharmaceutical-industry revenue by the year 2020. However, holding on to a head-start in oncology is difficult; a unique mix of innovation and risk taking is mandatory. Recent successes, such as PARP inhibition in ovarian cancer, anti-PD-1/anti-CTLA-4 combination therapies in melanoma, and CD38-targeting therapies in multiple myeloma, are offset by failures in other domains.
Global spending on cancer therapies continues to increase with spending on therapeutic and supportive care at USD 133 billion in 2017, up from USD 96 billion in 2013. The expenditure on cancer therapeutics is heavily concentrated among a fistful of therapies, with the top 35 cancer drugs accounting for nearly 80% of the total expenditure. Interestingly, over half of the cancer drugs have less than USD 90 million in annual sales due to a focus on niche tumors.
The world has come a long way since the declaration of war against cancer by the U.S. President Richard Nixon through the National Cancer Act of 1971. It is now clear that that the disease is more complex than previously anticipated. Nonetheless, there have been huge improvements in the understanding of the molecular mechanisms underlying the disease. Every day, more and more data is being generated and old hypotheses are either being renewed or altered altogether.
In these times of dynamic change, journals play an essential role in dispersal of scholarly information. Omics International, the leading open access publisher has an impressive portfolio of more than a thousand scientific journals, of these 62 are oncology related. Some of these like Journal of Carcinogenesis & Mutagenesis, Journal of Oncology Research and Treatment, Journal of Cancer Science & Therapy, and Journal of Nuclear Medicine & Radiation Therapy hold a prominent position in the scientific communication milieu.
Dr. Srinubabu Gedela, the CEO of Omics International understands the challenges associated with oncology research, and appreciates the hydra-like complexity of this disorder. He believes that the dynamic changes in the field need to be transmitted to researchers and medical professionals with equal rapidity in order to take advantage of these research findings and translate them into a robust cure for the disease. Notably, the open access format allows the public to understand how their money is translated into a better and healthier future for mankind.
The oncology journals published by Omics serve as the repository of the most comprehensive and original information on the latest developments in oncology. These journals deal with all aspects of cancer such as cellular and molecular biology of cancer, resistance to cancer therapies, and the development of better cancer therapeutics.
Abhishek Babu, PULSUS GROUP, http://www.pulsus.com, +91 4047482201, [email protected]
Share this article